Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hey

Showing results (211-220 of 228) with videos related to

Pageof 23
Sort By:
Spine Deformity|December 9, 2016
Adult Spinal Deformity: Epidemiology, Health Impact, Evaluation, and ManagementChristopher P Ames, Justin K Scheer, Virginie Lafage, et al.
Spine|June 14, 2017
Results of the 2015 Scoliosis Research Society Survey on Single Versus Dual Attending Surgeon Approach for Adult Spinal Deformity SurgeryJustin K Scheer, Rajiv K Sethi, Lloyd A Hey, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 15, 2007
A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammationRichard W Chapman, Michael Minnicozzi, Chander S Celly, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2003
Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687)Robbie L McLeod, Charlie A Rizzo, Robert E West, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2013
Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonistsQingbei Zeng, Stuart B Rosenblum, Zhaoxia Yang, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2010
The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonistsPauline C Ting, Joe F Lee, Margaret M Albanese, et al.
Pharmacology|August 22, 2009
Effect of a novel NOP receptor agonist (SCH 225288) on guinea pig irritant-evoked, feline mechanically induced and canine infectious tracheobronchitis coughRobbie L McLeod, Deen B Tulshian, Ginny D Ho, et al.
Spine|March 27, 2015
Results of the 2014 SRS Survey on PJK/PJF: A Report on Variation of Select SRS Member Practice Patterns, Treatment Indications, and Opinions on Classification DevelopmentJustin K Scheer, Shayan Fakurnejad, Darryl Lau, et al.
Drugs|September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 TrialSusan Abushakra, Aidan Power, David Watson, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2002
Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) templateRobert Aslanian, Mwangi W Mutahi, Neng Yang Shih, et al.
Pageof 23

Showing results (211-220 of 228) with videos related to

Sort By:
Pageof 23
Spine Deformity|December 9, 2016
Adult Spinal Deformity: Epidemiology, Health Impact, Evaluation, and ManagementChristopher P Ames, Justin K Scheer, Virginie Lafage, et al.
Spine|June 14, 2017
Results of the 2015 Scoliosis Research Society Survey on Single Versus Dual Attending Surgeon Approach for Adult Spinal Deformity SurgeryJustin K Scheer, Rajiv K Sethi, Lloyd A Hey, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 15, 2007
A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammationRichard W Chapman, Michael Minnicozzi, Chander S Celly, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2003
Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687)Robbie L McLeod, Charlie A Rizzo, Robert E West, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2013
Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonistsQingbei Zeng, Stuart B Rosenblum, Zhaoxia Yang, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2010
The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonistsPauline C Ting, Joe F Lee, Margaret M Albanese, et al.
Pharmacology|August 22, 2009
Effect of a novel NOP receptor agonist (SCH 225288) on guinea pig irritant-evoked, feline mechanically induced and canine infectious tracheobronchitis coughRobbie L McLeod, Deen B Tulshian, Ginny D Ho, et al.
Spine|March 27, 2015
Results of the 2014 SRS Survey on PJK/PJF: A Report on Variation of Select SRS Member Practice Patterns, Treatment Indications, and Opinions on Classification DevelopmentJustin K Scheer, Shayan Fakurnejad, Darryl Lau, et al.
Drugs|September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 TrialSusan Abushakra, Aidan Power, David Watson, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2002
Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) templateRobert Aslanian, Mwangi W Mutahi, Neng Yang Shih, et al.
Pageof 23